GlaxoSmithKline Extends GeneGo License and Adds New Products
News Feb 19, 2008
GeneGo, Inc. announced that GlaxoSmithKline has extended their licensing agreement with GeneGo and have added additional capability. This will provide GlaxoSmithKline researchers with global access to MetaCore, MapEditor and MetaBase.
MetaCore is GeneGo’s flagship platform for functional analysis of biological OMICs data featuring a comprehensive collection of pathway maps and network models for cellular processes and common diseases.
MetaCore is used for target identification, validation, biomarker discovery and knowledge mining. GlaxoSmithKline will also use the platform as a repository of all types of experimental data as well as resulting analyses.
All of this information can be shared with individuals or groups. MetaBase is direct access to the manually curated database of pathways, networks, ontologies, medicinal chemistry and diseases covering human, mouse and rat. MapEditor is a powerful research tool for creating intereractive custom maps which amalgamate MetaBase knowledge content with proprietary information and data.
“We have a good working relationship with GlaxoSmithKline developing new products such as our pay as you go 1-2-3 Workflow,” said Julie Bryant, GeneGo’s VP of Business development. “We will continue to work closely developing new functionality, tools and content for GlaxoSmithKline.”
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE